{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T12:52:24Z","timestamp":1760100744348},"reference-count":75,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1097\/pap.0000000000000065","type":"journal-article","created":{"date-parts":[[2015,4,4]],"date-time":"2015-04-04T06:17:54Z","timestamp":1428128274000},"page":"168-180","source":"Crossref","is-referenced-by-count":8,"title":["Aggressive B-Cell Lymphomas"],"prefix":"10.1097","volume":"22","author":[{"given":"Michael T.","family":"Schmidt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serhan","family":"Alkan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-2-20210202","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","article-title":". The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications.","volume":"117","author":"Campo","year":"2011","journal-title":"Blood"},{"key":"R2-2-20210202","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","article-title":". Chronic active B-cell-receptor signaling in diffuse large B-cell lymphoma.","volume":"463","author":"Davis","year":"2010","journal-title":"Nature"},{"key":"R3-2-20210202","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":". Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"key":"R4-2-20210202","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/ng.892","article-title":". Analysis of the coding genome of diffuse large B-cell lymphoma.","volume":"43","author":"Pasqualucci","year":"2011","journal-title":"Nat Genet"},{"key":"R5-2-20210202","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":". The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma.","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N Engl J Med"},{"key":"R6-2-20210202","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S1470-2045(09)70351-1","article-title":"Common misdiagnoses in lymphomas and avoidance strategies.","volume":"11","author":"Chan","year":"2010","journal-title":"Lancet Oncol"},{"key":"R7-2-20210202","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.1986.4.10.1470","article-title":". Follicular lymphoma: prognostic factors for response and survival.","volume":"4","author":"Gallagher","year":"1986","journal-title":"J Clin Oncol"},{"key":"R8-2-20210202","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s11912-012-0258-4","article-title":"Transformation in follicular lymphoma: biology, prognosis, and therapeutic options.","volume":"14","author":"Wong","year":"2012","journal-title":"Curr Oncol Rep"},{"key":"R9-2-20210202","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1365-2141.2010.08331.x","article-title":". Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI).","volume":"151","author":"Advani","year":"2010","journal-title":"Br J Haematol"},{"key":"R10-2-20210202","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","article-title":". Stromal gene signatures in large-B-cell lymphomas.","volume":"359","author":"Lenz","year":"2008","journal-title":"N Engl J Med"},{"key":"R11-2-20210202","doi-asserted-by":"crossref","first-page":"6069","DOI":"10.1182\/blood-2009-01-199679","article-title":". Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma.","volume":"113","author":"Dunleavy","year":"2009","journal-title":"Blood"},{"key":"R12-2-20210202","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/MOH.0b013e32834706ee","article-title":"Molecular signatures in the diagnosis and management of diffuse large B-cell lymphoma.","volume":"18","author":"Sweetenham","year":"2011","journal-title":"Curr Opin Hematol"},{"key":"R13-2-20210202","doi-asserted-by":"crossref","first-page":"4836","DOI":"10.1182\/blood-2010-12-322362","article-title":". Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.","volume":"117","author":"Gutierrez-Garcia","year":"2011","journal-title":"Blood"},{"key":"R14-2-20210202","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":". Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"key":"R15-2-20210202","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1182\/blood-2012-10-460063","article-title":". MYCBCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program.","volume":"121","author":"Hu","year":"2013","journal-title":"Blood"},{"key":"R16-2-20210202","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/bjh.12763","article-title":". MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab.","volume":"165","author":"Perry","year":"2014","journal-title":"Br J Haemotol"},{"key":"R17-2-20210202","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1038\/leu.2012.83","article-title":". Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the international DLBCL Rituximab-CHOP Consortium Program Study.","volume":"26","author":"Visco","year":"2012","journal-title":"Leukemia"},{"key":"R18-2-20210202","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-09-0113","article-title":". A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy.","volume":"15","author":"Choi","year":"2009","journal-title":"Clin Cancer Res"},{"key":"R19-2-20210202","doi-asserted-by":"crossref","first-page":"7070","DOI":"10.1182\/blood-2011-04-345256","article-title":". Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium.","volume":"117","author":"Salles","year":"2011","journal-title":"Blood"},{"key":"R20-2-20210202","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1200\/JCO.2010.30.0368","article-title":". Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab.","volume":"29","author":"Meyer","year":"2011","journal-title":"J Clin Oncol"},{"key":"R21-2-20210202","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1200\/JCO.2011.41.4342","article-title":". Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.","volume":"30","author":"Green","year":"2012","journal-title":"J Clin Oncol"},{"key":"R22-2-20210202","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00428-011-1165-z","article-title":"De Wolf-Peeters C. T cellhistiocyte-rich large B-cell lymphoma: an update on its biology and classification.","volume":"459","author":"Tousseyn","year":"2011","journal-title":"Virchows Arch"},{"key":"R23-2-20210202","first-page":"1269","article-title":". T-cellhistiocyte-rich large B-cell lymphoma: a distinct clinicopathologic entity.","volume":"20","author":"Achten","year":"2002","journal-title":"J Clin Oncol"},{"key":"R24-2-20210202","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1634\/theoncologist.11-4-384","article-title":"T-cellhistiocyte-rich B-cell lymphoma: biology, diagnosis, and management.","volume":"11","author":"Abramson","year":"2006","journal-title":"Oncologist"},{"key":"R25-2-20210202","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1182\/blood-2003-02-0626","article-title":". Nodular lymphocyte-predominant Hodgkin lymphoma with nodules resembling T-cellhistiocyte-rich B-cell lymphoma: differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cellhistiocyte-rich B-cell lymphoma.","volume":"102","author":"Boudova","year":"2003","journal-title":"Blood"},{"key":"R26-2-20210202","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1097\/PAS.0b013e318165b0d6","article-title":". PD-1, a follicular T-cell marker useful for recognizing nodular lymphocyte-predominant Hodgkin lymphoma.","volume":"32","author":"Nam-Cha","year":"2008","journal-title":"Am J Surg Pathol"},{"key":"R27-2-20210202","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.1158\/1078-0432.CCR-06-2823","article-title":". Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients.","volume":"13","author":"Oyama","year":"2007","journal-title":"Clin Cancer Res"},{"key":"R28-2-20210202","doi-asserted-by":"crossref","first-page":"4726","DOI":"10.1182\/blood-2010-12-323238","article-title":". Age-related EBV-associated lymphoproliferative disorders in the Western population: a spectrum of reactive lymphoid hyperplasia and lymphoma.","volume":"117","author":"Dojcinov","year":"2011","journal-title":"Blood"},{"key":"R29-2-20210202","first-page":"111","article-title":". Lymphomatoid granulomatosis: a practical review for pathologists dealing with this rare pulmonary lymphoproliferative process.","volume":"105","author":"Tagliavini","year":"2013","journal-title":"Pathologica"},{"key":"R31-2-20210202","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1182\/blood.V72.5.1674.1674","article-title":". Angiocentric immunoproliferative lesions: a clinicopathologic spectrum of post-thymic T-cell proliferations.","volume":"72","author":"Lipford","year":"1988","journal-title":"Blood"},{"key":"R32-2-20210202","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1097\/00000478-199809000-00008","article-title":". Proliferation and cellular phenotype in lymphomatoid granulomatosis: implications of a higher proliferation index in B cells.","volume":"22","author":"Guinee","year":"1998","journal-title":"Am J Surg Pathol"},{"key":"R33-2-20210202","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1097\/01.pas.0000126781.87158.e3","article-title":". Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities.","volume":"28","author":"Colomo","year":"2004","journal-title":"Am J Surg Pathol"},{"key":"R34-2-20210202","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/modpathol.3800355","article-title":". Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles.","volume":"18","author":"Vega","year":"2005","journal-title":"Mod Pathol"},{"key":"R35-2-20210202","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1056\/NEJM199505043321802","article-title":". Kaposis sarcoma-associated herpes virus-like DNA sequences in AIDS-related body-cavity-based lymphomas.","volume":"332","author":"Cesarman","year":"1995","journal-title":"N Engl J Med"},{"key":"R36-2-20210202","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1097\/01.pas.0000138177.10829.5c","article-title":". KSHV-positive solid lymphomas represent an extra-cavitary variant of primary effusion lymphoma.","volume":"28","author":"Chadburn","year":"2004","journal-title":"Am J Surg Pathol"},{"key":"R37-2-20210202","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1097\/PAS.0b013e31825b38ec","article-title":". Extracavitary KSHV-associated large B-Cell lymphoma: a distinct entity or a subtype of primary effusion lymphoma Study of 9 cases and review of an additional 43 cases.","volume":"36","author":"Pan","year":"2012","journal-title":"Am J Surg Pathol"},{"key":"R38-2-20210202","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/modpathol.2010.72","article-title":". Plasmablastic lymphoma with MYC translocation: evidence for a common pathway in the generation of plasmablastic features.","volume":"23","author":"Taddesse-Heath","year":"2010","journal-title":"Mod Pathol"},{"key":"R39-2-20210202","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1097\/PAS.0b013e3181f3e29f","article-title":". IGMYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas.","volume":"34","author":"Valera","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"R40-2-20210202","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/gcc.20563","article-title":". Secondary genomic rearrangements involving immunoglobulin or MYC loci show similar prevalences in hyperdiploid and nonhyperdiploid myeloma tumors.","volume":"47","author":"Gabrea","year":"2008","journal-title":"Genes Chromosomes Cancer"},{"key":"R41-2-20210202","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.4161\/cbt.10.10.13291","article-title":". Kaposi sarcoma-associated herpes virus-encoded viral FLICE inhibitory protein (vFLIP) K13 cooperates with Myc to promote lymphoma in mice.","volume":"10","author":"Ahmad","year":"2010","journal-title":"Cancer Biol Ther"},{"key":"R42-2-20210202","doi-asserted-by":"crossref","first-page":"4979","DOI":"10.1038\/sj.onc.1210299","article-title":"Deregulation of c-Myc in primary effusion lymphoma by Kaposis sarcoma herpes virus latency-associated nuclear antigen.","volume":"26","author":"Bubman","year":"2007","journal-title":"Oncogene"},{"key":"R43-2-20210202","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/PAS.0b013e318267fabc","article-title":". KSHVHHV8-negative effusion-based lymphoma, a distinct entity associated with fluid overload states.","volume":"37","author":"Alexanian","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"R44-2-20210202","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1182\/blood.V89.5.1483","article-title":". A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2;5 translocation.","volume":"89","author":"Delsol","year":"1997","journal-title":"Blood"},{"key":"R45-2-20210202","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3324\/haematol.2010.031484","article-title":". Cytogenetically complex SEC31A-ALK fusions are recurrent in ALK-positive large B-cell lymphomas.","volume":"96","author":"Bedwell","year":"2011","journal-title":"Haematologica"},{"key":"R46-2-20210202","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1155\/2012\/529572","article-title":"Anaplastic lymphoma kinase-positive large B-cell lymphoma: an underrecognized aggressive lymphoma.","volume":"2012","author":"Morgan","year":"2012","journal-title":"Adv Hematol"},{"key":"R47-2-20210202","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1200\/JCO.2006.08.2313","article-title":". Definition, diagnosis, and management of intravascular large B-cell lymphoma: proposals and perspectives from an international consensus meeting.","volume":"25","author":"Ponzoni","year":"2007","journal-title":"J Clin Oncol"},{"key":"R48-2-20210202","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/j.0303-6987.2005.00495.x","article-title":". WHOEORTC classification of cutaneous lymphomas 2005: histological and molecular aspects.","volume":"32","author":"Burg","year":"2005","journal-title":"J Cutan Pathol"},{"key":"R49-2-20210202","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1182\/blood-2005-02-0542","article-title":". Comparison of genome profiles for identification of distinct subgroups of diffuse large-B-cell lymphoma.","volume":"106","author":"Tagawa","year":"2005","journal-title":"Blood"},{"key":"R50-2-20210202","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1182\/blood-2006-01-021253","article-title":". Intravascular large B-cell lymphoma (IVLBCL): a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5.","volume":"109","author":"Murase","year":"2007","journal-title":"Blood"},{"key":"R51-2-20210202","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1182\/blood-2011-03-321349","article-title":"How I treat primary CNS lymphoma..","volume":"118","author":"Ferreri","year":"2011","journal-title":"Blood"},{"key":"R52-2-20210202","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/NEN.0000000000000076","article-title":"CNS lymphoma: a practical diagnostic approach.","volume":"73","author":"Giannini","year":"2014","journal-title":"J Neuropathol Exp Neurol"},{"key":"R53-2-20210202","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":". WHO-EORTC classification for cutaneous lymphomas.","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"key":"R54-2-20210202","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1182\/blood-2004-04-1594","article-title":". Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling.","volume":"105","author":"Hoefnagel","year":"2005","journal-title":"Blood"},{"key":"R55-2-20210202","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1182\/blood-2003-08-2726","article-title":". Bcl-2 protein expression is the strongest independent prognostic factor of survival in primary cutaneous large B-cell lymphomas.","volume":"103","author":"Grange","year":"2004","journal-title":"Blood"},{"key":"R56-2-20210202","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1182\/blood-2014-03-564906","article-title":". A prospective study of mediastinal gray zone lymphoma.","volume":"124","author":"Wilson","year":"2014","journal-title":"Blood"},{"key":"R57-2-20210202","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3324\/haematol.2010.030809","article-title":". Clinical, pathological and genetic features of primary mediastinal large B-cell lymphoma and mediastinal gray zone lymphomas in children.","volume":"96","author":"Oschlies","year":"2011","journal-title":"Haematologica"},{"key":"R58-2-20210202","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":". Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"key":"R59-2-20210202","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1182\/blood-2004-12-4901","article-title":". NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes.","volume":"106","author":"Feuerhake","year":"2005","journal-title":"Blood"},{"key":"R60-2-20210202","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1182\/blood-2003-06-1841","article-title":". The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma.","volume":"102","author":"Savage","year":"2003","journal-title":"Blood"},{"key":"R61-2-20210202","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1097\/01.pas.0000180856.74572.73","article-title":". Mediastinal gray zone lymphoma: the missing link between classic Hodgkins lymphoma and mediastinal large B-cell lymphoma.","volume":"29","author":"Traverse-Glehen","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"R62-2-20210202","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1136\/jcp.2007.047969","article-title":"Kaposi sarcoma-associated herpes virushuman herpes virus 8 and lymphoproliferative disorders.","volume":"60","author":"Du","year":"2007","journal-title":"J Clin Pathol"},{"key":"R63-2-20210202","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1365-2559.2008.03144.x","article-title":". Immunophenotypic analysis of the Kaposi sarcoma herpes virus (KSHV; HHV-8)-infected B cells in HIV multicentric Castleman disease (MCD).","volume":"53","author":"Chadburn","year":"2008","journal-title":"Histopathology"},{"key":"R64-2-20210202","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1182\/blood-2011-08-373738","article-title":"How I treat HIV-associated lymphoma.","volume":"119","author":"Dunleavy","year":"2012","journal-title":"Blood"},{"key":"R65-2-20210202","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S0140-6736(11)61177-X","article-title":". Burkitts lymphoma.","volume":"379","author":"Molyneux","year":"2012","journal-title":"Lancet"},{"key":"R66-2-20210202","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/PAS.0000000000000147","article-title":". Clinical significance of MYC expression andor high grade morphology in non-Burkitt, diffuse aggressive B-cell lymphomas: a SWOG S9704 correlative study.","volume":"38","author":"Cook","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"R67-2-20210202","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1182\/blood-2010-09-297879","article-title":". Double-hit B-cell lymphomas.","volume":"117","author":"Aukema","year":"2011","journal-title":"Blood"},{"key":"R68-2-20210202","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/PAS.0b013e3181cd3aeb","article-title":". B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.","volume":"34","author":"Snuderl","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"R69-2-20210202","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1002\/cncr.26433","article-title":". Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma.","volume":"118","author":"Lin","year":"2012","journal-title":"Cancer"},{"key":"R70-2-20210202","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","article-title":". Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone.","volume":"30","author":"Johnson","year":"2012","journal-title":"J Clin Oncol"},{"key":"R71-2-20210202","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature09671","article-title":". Oncogenically active MYD88 mutations in human lymphoma..","volume":"470","author":"Ngo","year":"2011","journal-title":"Nature"},{"key":"R72-2-20210202","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.1182\/blood-2012-06-436329","article-title":". MYD88 L265P mutation in Waldenstrom macroglobulinemia.","volume":"121","author":"Poulain","year":"2013","journal-title":"Blood"},{"key":"R73-2-20210202","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/nrclinonc.2013.197","article-title":"Diffuse large B-cell lymphoma-treatment approaches in the molecular era.","volume":"11","author":"Roschewski","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"R74-2-20210202","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ccr.2012.05.024","article-title":". Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma.","volume":"21","author":"Yang","year":"2012","journal-title":"Cancer Cell"},{"key":"R75-2-20210202","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature11606","article-title":". EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.","volume":"492","author":"McCabe","year":"2012","journal-title":"Nature"},{"key":"R76-2-20210202","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1158\/1535-7163.MCT-13-0773","article-title":". Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma.","volume":"13","author":"Knutson","year":"2014","journal-title":"Mol Cancer Ther"}],"container-title":["Advances in Anatomic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAP.0000000000000065","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T07:25:39Z","timestamp":1651649139000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00125480-201505000-00002"}},"subtitle":["A Review and Practical Approach for the Practicing Pathologist"],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":75,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/pap.0000000000000065","relation":{},"ISSN":["1072-4109"],"issn-type":[{"value":"1072-4109","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]}}}